Bioavailability

Novo Nordisk Licenses Vivtex Platform in $2.1 Billion Push for Oral Obesity and Diabetes Drugs

The pact taps an AI-enabled gut-on-a-chip platform to turn injectable peptides into pills in a crowded GLP-1 market.